Trade name
Milrinone-Baxter, Milrinone GH
Strength
1 mg/mL (volume: 10 mL)
IV administration
Milrinone should be administered by a dedicated line. Refer to relevant local guideline for further administration information.
Loading dose: Give undiluted or dilute to a convenient volume and give over 10 minutes to 1 hour.
Continuous infusion: Dilute to 200 microgram/mL or weaker.
Neonates: Administration via a large peripheral vein, preferably via a central line. Administration into an umbilical arterial catheter is not recommended.
Maximum concentration if necessary: 800 microgram/mL via a central line only.
RCH Standard Concentrations:
NICU:
0 to < 2 kg: 2.5 mg/25 mL (0.1 mg/mL)
2 kg+: 5 mg/25 mL (0.2 mg/mL)
Fluid restricted: 10 mg/25 mL (0.4 mg/mL)
Other:
0 to < 10 kg: 10 mg/50 mL (0.2 mg/mL)
Fluid restricted: 20 mg/50 mL (0.4 mg/mL)
10 to < 40 kg: 10 mg/50 mL (0.2 mg/mL)
Fluid restricted: 40 mg/50 mL (0.8 mg/mL)
40 kg+: 20 mg/100 mL (0.2 mg/mL)
Fluid restricted: 40 mg/100 mL (0.4 mg/mL)
Other routes of administration
IM: Not recommended.
SC: Not recommended.
Compatible IV fluids
Glucose 5%
Sodium chloride 0.9%
Milrinone 400 microgram/mL or weaker:
Hartmann's
Y-site only:
Potassium chloride 20 mmol/L
Y-site only and milrinone 300 microgram/mL or weaker:
Plasma-Lyte 148
Additional information
Extravasation risk.
Administration may cause hypotension. To minimise risk, loading dose can be given over up to 1 hour or divided into 5 equal doses over 10 minutes each, or omitted. Refer to relevant local guideline.
Continuous cardiac monitoring required. Taper the infusion slowly when discontinuing treatment.
Solution should be clear and colourless to pale yellow.
Milrinone GH: Protect from light during storage.